U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosisCompany expands pipeline through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results